BioNTech ADR saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 73.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of over 80 as they launch their biggest climbs. See if BioNTech ADR can continue to rebound and hit that benchmark.
While the stock is not near a proper entry right now, see if it manages to form and break out from a proper chart pattern.
Top and bottom line growth moved higher last quarter. Earnings were up 0%, compared to -46% in the prior report. Revenue increased from -25% to -2%.
The company holds the No. 218 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
